Orlagh is a Postdoctoral Fellow and Nanomedicine team lead in the Porter Group at Monash Institute of Pharmaceutical Sciences (MIPS). Prior to relocating to Australia, she spent six years in pharmaceutical R&D in Ireland, at preclinical and early phase one/two clinical level. As a result, she maintains a strong translational focus to her work.

Orlagh’s expertise is in advanced drug delivery, with specific interest in controlling pharmacokinetics, lymphatic exposure and drug deposition in cancer and autoimmunity. This is achieved with multiple strategies, including active targeting, stromal modification and manipulation of physicochemical characteristics. Orlagh has extensive experience in preclinical study design and has established multiple disease models to examine new drug delivery strategies, including solid or disseminated cancers and collagen induced arthritis.